Testing a new drug for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced stomach cancer or cancer where the stomach meets the esophagus that has spread or cannot be removed by surgery.
- You have either HER2-negative cancer, or HER2-positive cancer that got worse after HER2-targeted treatment.
- You have tried at least one prior cancer treatment and your cancer got worse or came back.
- You do not have certain other serious medical conditions (like active brain tumors, autoimmune disease, or uncontrolled infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (ONO-4578) combined with the usual immunotherapy (nivolumab) and chemotherapy for stomach cancer that has not been treated before. It aims to see if adding this drug helps shrink tumors or slows disease growth better than placebo.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.